The AMR Action Fund announces appointment of CEO, Henry B. Skinner, PhD
Today, the AMR Action Fund announced the appointment of its first Chief Executive Officer (CEO), Henry B. Skinner, PhD. The AMR Action Fund (www.AMRactionfund.com) is a ground-breaking partnership that was launched in July 2020 by more than 20 leading pharmaceutical companies. It aims to invest over US$1 billion to strengthen and accelerate clinical research of innovative new antibiotics that are addressing the most resistant bacteria and life-threatening infections, as well as provide technical support to biotech companies developing assets in this field. The AMR Action Fund is the largest collaborative venture ever created to address antimicrobial resistance (AMR).
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!